HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group
Advertisement

Related Content

DEA Proposes Registration Fee Increases To Fund Diversion Control Program
FDA-Proposed Warning For OTC Bronchodilators “Alarming” – Wyeth
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule

Topics

Advertisement
UsernamePublicRestriction

Register

PS098962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel